Related Experiment Videos
Calcium ketovaline as new therapy for uremic hyperphosphatemia
K Schaefer1, D von Herrath, C M Erley
1Medizinische Abteilung II, St. Joseph-Krankenhaus I, Berlin.
Mineral and Electrolyte Metabolism
|January 1, 1990
Summary
Calcium ketovaline effectively binds intestinal phosphate, offering a safer alternative for managing hyperphosphatemia in dialysis patients. This study demonstrates its significant phosphate-lowering effects.
Area of Science:
- Nephrology
- Biochemistry
Background:
- Uremic hyperphosphatemia is a significant clinical challenge.
- Traditional phosphate binders, like aluminum-based agents, pose risks such as aluminum intoxication.
- Novel phosphate-binding agents are needed to improve patient safety and treatment efficacy.
Purpose of the Study:
- To evaluate calcium ketovaline as an intestinal phosphate binder.
- To compare its efficacy against previously studied amino acid and keto-analogue mixtures.
- To assess its safety and effectiveness in dialysis patients.
Main Methods:
- In vitro experiments to assess phosphate-binding capacity.
- In vivo studies in dialysis patients over a 6-week treatment period.
- Measurement of serum phosphate levels before and after treatment.
Main Results:
- Calcium ketovaline demonstrated significant intestinal phosphate-binding properties in vitro.
- In vivo studies showed a statistically significant reduction in serum phosphate levels (p < 0.05).
- Serum phosphate decreased from a mean of 2.36 +/- 0.19 to 1.81 +/- 0.16 mmol/l over 6 weeks.
Conclusions:
- Calcium ketovaline is a valuable intestinal phosphate binder.
- It offers a promising therapeutic option for managing hyperphosphatemia in dialysis patients.
- Further research may explore its long-term efficacy and safety profile.